XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
Launched by ABBOTT MEDICAL DEVICES · Aug 7, 2008
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
This study will evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary Stent system (XIENCE V®) acute performance, deliverability and resource utilization in the catheterization lab in the "real world" as used by a broad group of physicians at a variety of health care facilities. This study will include all consecutively enrolled patients in the United States of America (USA) who consent to participate and receive XIENCE V® stents.
Gender
ALL
Eligibility criteria
- General Inclusion Criteria:
- • The patient agrees to participate in this study by signing the IRB approved informed consent form prior to the index procedure.
- • Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form prior to the index procedure.
- General Exclusion Criteria:
- • Inability to obtain an informed consent is an exclusion criterion.
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pomona, New Jersey, United States
Farmington, Connecticut, United States
Elgin, Illinois, United States
Iowa City, Iowa, United States
Jackson, Michigan, United States
Ocala, Florida, United States
Des Moines, Iowa, United States
La Mesa, California, United States
Phoenixville, Pennsylvania, United States
St. Louis, Missouri, United States
Reno, Nevada, United States
Marion, Ohio, United States
Albuquerque, New Mexico, United States
Jonesboro, Arkansas, United States
Huntsville, Alabama, United States
Fort Wayne, Indiana, United States
Bristol, Tennessee, United States
Colorado Springs, Colorado, United States
Midland, Michigan, United States
Kansas City, Missouri, United States
Oklahoma City, Oklahoma, United States
Mesa, Arizona, United States
Hot Springs National Park, Arkansas, United States
Hot Springs Village, Arkansas, United States
Bradenton, Florida, United States
Rome, Georgia, United States
Mokena, Illinois, United States
Indianapolis, Indiana, United States
Muncie, Indiana, United States
Hutchinson, Kansas, United States
Saginaw, Michigan, United States
Biloxi, Mississippi, United States
Pinehurst, North Carolina, United States
Fairfield, Ohio, United States
Johnstown, Pennsylvania, United States
Lebanon, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Columbia, South Carolina, United States
Rock Hill, South Carolina, United States
Tomball, Texas, United States
Richmond,, Virginia, United States
Virginia Beach,, Virginia, United States
Charleston, West Virginia, United States
Patients applied
Trial Officials
John McPherson, MD
Principal Investigator
Vanderbuilt University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials